Key Highlights
- Phase 2 SKYWAY-RA results for SPY072 reached statistical significance over placebo across primary metrics with a comparable safety profile.
- Efficacy magnitude fell short of the company’s internal benchmarks for rheumatoid arthritis monotherapy.
- Focus moves to psoriatic arthritis and axial spondyloarthritis data in late 2026 and hidradenitis suppurativa combination trials by early 2028. Shares closed down 13 per cent at USD 93.61.
Spyre Therapeutics (NASDAQ: SYRE) has released Phase 2 SKYWAY-RA results for SPY072. The company reported that the candidate demonstrated statistical significance over placebo across primary clinical metrics with a comparable safety profile. It also stated that the magnitude of efficacy fell short of internal benchmarks for rheumatoid arthritis monotherapy, and set out a redirection of focus toward other indications. Shares closed down 13 per cent at USD 93.61.
Statistical significance and clinical magnitude are separate questions
The distinction sits at the centre of this result. Statistical significance answers whether an observed difference is unlikely to be chance. Magnitude of effect answers how large that difference is. A trial can clear the first test and still produce an effect size that a developer judges insufficient to compete in an indication, which is what the company has described here.
Spyre stated the shortfall was against internal benchmarks for rheumatoid arthritis monotherapy specifically. The company has not disclosed what those benchmarks were, so the size of the gap cannot be assessed from outside. Safety was reported as comparable to placebo, and no safety issue was cited as part of the redirection.
Where the programme goes next
Three items were named. Psoriatic arthritis and axial spondyloarthritis data are expected in late 2026. Hidradenitis suppurativa combination trials are expected by early 2028. The RA monotherapy positioning is no longer the stated near-term priority for SPY072. That places the next meaningful readout for the asset in the second half of 2026 on the company’s own timeline.
What was not disclosed
The information reviewed did not include the internal efficacy benchmarks, effect sizes or response rates on the primary metrics, patient numbers, dosing regimens, the specific endpoints used, or any detail on how the combination approach in hidradenitis suppurativa would be constructed. The gap between reported significance and the company’s own bar cannot be quantified from the disclosure.
This article is general information only and does not take into account any individual objectives, financial situation or needs. It is not a recommendation to buy, sell or hold any security. All details are as stated in the company announcement or third party research referenced and are subject to change. Past performance is not a reliable indicator of future performance. Investors should consider the appropriateness of any information having regard to their own circumstances and seek independent financial advice before making any financial decision.






Please wait processing your request...